Integrated Diagnostics Financials

IDHC Stock   0.45  0.02  4.65%   
We strongly advise to harness Integrated Diagnostics analysis to find out if markets are presently mispricing the company. We are able to interpolate and collect twenty-seven available reported financial drivers for Integrated Diagnostics, which can be compared to its competitors. The stock experiences a very speculative upward sentiment. Check odds of Integrated Diagnostics to be traded at 0.5625 in 90 days. Key indicators impacting Integrated Diagnostics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Operating Income765.5 M737.8 M
Sufficiently Up
Slightly volatile
  
Understanding current and past Integrated Diagnostics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Integrated Diagnostics' financial statements are interrelated, with each one affecting the others. For example, an increase in Integrated Diagnostics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Integrated Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Integrated Diagnostics Holdings. Check Integrated Diagnostics' Beneish M Score to see the likelihood of Integrated Diagnostics' management manipulating its earnings.

Integrated Diagnostics Stock Summary

Integrated Diagnostics competes with Lloyds Banking, SANTANDER, Vodafone Group, and Vodafone Group. Integrated Diagnostics is entity of United Kingdom. It is traded as Stock on LSE exchange.
Foreign Associate
  Egypt
Specialization
Health Care, Health Care Equipment & Services
InstrumentUK Stock View All
ExchangeLondon Exchange
ISINJE00BLKGSR75
Business AddressIFC 5, Saint
SectorHealth Care Providers & Services
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.idhcorp.com
Phone44 15 3484 7000
You should never invest in Integrated Diagnostics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Integrated Stock, because this is throwing your money away. Analyzing the key information contained in Integrated Diagnostics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Integrated Diagnostics Key Financial Ratios

There are many critical financial ratios that Integrated Diagnostics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Integrated Diagnostics reports annually and quarterly.

Integrated Diagnostics Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets3.8B4.2B6.2B5.3B5.8B4.1B
Other Current Liab374.0M488.3M1.4B871.0M679.8M412.0M
Net Debt35.9M(48.1M)(793.4M)(532.1M)504.9M530.2M
Retained Earnings456.7M603.3M1.6B783.1M1.3B1.3B
Accounts Payable145.2M177.6M311.3M269.8M271.7M165.7M
Cash408.9M600.1M891.5M648.5M674.3M572.3M
Net Receivables261.7M326.8M373.9M397.5M571.5M600.1M
Good Will1.3B1.3B1.3B1.3B1.3B1.4B
Inventory84.3M100.1M222.6M265.5M374.7M393.4M
Other Current Assets61.4M56.7M95.9M146.4M155.7M163.5M
Total Liab1.4B1.8B3.4B2.8B2.7B1.5B
Total Current Assets1.0B1.4B3.0B1.6B2.0B1.3B
Short Term Debt87.1M85.9M137.2M171.4M220.4M231.4M
Intangible Assets398.6M399.8M402.5M418.2M422.9M335.8M
Other Liab196.8M209.3M275.5M371.3M427.0M222.5M
Net Tangible Assets597.6M554.7M610.2M924.0M1.1B551.2M
Long Term Debt81.3M67.6M76.3M93.8M67.5M58.8M
Net Invested Capital2.3B2.4B2.7B2.3B2.8B2.7B
Net Working Capital209.7M351.0M693.6M160.2M686.9M468.6M

Integrated Diagnostics Key Income Statement Accounts

201920202021202220232024 (projected)
Total Revenue2.2B2.7B5.2B3.6B4.1B2.3B
Gross Profit1.1B1.3B2.8B1.5B1.5B1.1B
Operating Income790.8M985.5M2.3B1.2B737.8M765.5M
Ebit819.1M1.0B2.3B976.3M879.0M776.5M
Ebitda972.6M1.2B2.6B1.3B1.3B951.5M
Cost Of Revenue1.1B1.3B2.4B2.1B2.6B2.7B
Income Before Tax758.1M969.1M2.2B853.6M737.4M729.5M
Net Income510.9M594.0M1.4B541.1M510.3M464.7M
Income Tax Expense253.6M359.6M739.8M327.1M269.0M258.1M
Interest Expense61.0M67.9M98.0M122.7M141.7M148.8M
Minority Interest144.7M156.4M(79.9M)14.5M41.9M60.1M
Tax Provision253.6M359.6M739.8M327.1M269.0M339.1M
Net Interest Income(21.0M)(18.4M)(4.9M)(40.2M)(88.2M)(83.8M)
Interest Income43.6M53.1M113.2M95.4M72.8M70.1M

Integrated Diagnostics Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory4.9M(17.1M)(127.6M)(30.2M)(104.9M)(99.7M)
Change In Cash(3.7M)191.2M291.3M(242.9M)25.7M24.5M
Free Cash Flow479.4M756.5M2.0B(100.1M)217.7M206.8M
Depreciation153.5M185.4M238.6M317.3M401.2M421.3M
Other Non Cash Items17.6M18.4M4.9M(704.4M)(199.9M)(189.9M)
Capital Expenditures218.0M126.0M263.7M308.8M325.9M179.8M
Net Income758.1M969.1M2.2B853.6M737.4M723.7M
End Period Cash Flow408.9M600.1M891.5M648.5M674.3M596.0M
Investments18.3M(55.0M)(1.3B)990.1M(243.9M)(231.7M)
Net Borrowings46.2M(84.6M)(56.4M)(54.6M)(49.1M)(46.7M)
Dividends Paid450.5M450.7M478.7M1.4B1.6B1.7B
Change To Netincome51.4M91.6M208.9M500.2M575.2M604.0M

Integrated Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Integrated Diagnostics's current stock value. Our valuation model uses many indicators to compare Integrated Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integrated Diagnostics competition to find correlations between indicators driving Integrated Diagnostics's intrinsic value. More Info.
Integrated Diagnostics Holdings is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about  0.42  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Integrated Diagnostics Holdings is roughly  2.38 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integrated Diagnostics' earnings, one of the primary drivers of an investment's value.

Integrated Diagnostics Systematic Risk

Integrated Diagnostics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Integrated Diagnostics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Integrated Diagnostics correlated with the market. If Beta is less than 0 Integrated Diagnostics generally moves in the opposite direction as compared to the market. If Integrated Diagnostics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Integrated Diagnostics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Integrated Diagnostics is generally in the same direction as the market. If Beta > 1 Integrated Diagnostics moves generally in the same direction as, but more than the movement of the benchmark.

Integrated Diagnostics Holdings Total Assets Over Time

Integrated Diagnostics December 22, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Integrated Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Integrated Diagnostics Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Integrated Diagnostics Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Integrated Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Integrated Diagnostics's daily price indicators and compare them against related drivers.

Additional Tools for Integrated Stock Analysis

When running Integrated Diagnostics' price analysis, check to measure Integrated Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Diagnostics is operating at the current time. Most of Integrated Diagnostics' value examination focuses on studying past and present price action to predict the probability of Integrated Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Diagnostics' price. Additionally, you may evaluate how the addition of Integrated Diagnostics to your portfolios can decrease your overall portfolio volatility.